Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 278 across all filing types
Latest filing 2023-04-17 Earnings Release
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Final Results
Earnings Release Classification · 99% confidence The document explicitly states it reports the 'audited results for the year ended 31 December 2022' and provides detailed 'Financial Highlights' and 'Operational Highlights' for the full year. The presence of 'audited results' and the comprehensive nature of the financial review strongly suggest this is the Annual Report, which corresponds to the 10-K filing type in the US context, or the primary annual filing. Although it is distributed via RNS (RNS Number : 3471W), the content itself is the full annual performance review, not just an announcement of its publication. Given the comprehensive financial data and the 'audited results' declaration, 10-K is the most appropriate classification for a full annual report. FY 2022
2023-04-17 English
PDMR Shareholding / Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an official notification released via RNS (RNS Number : 1969V) on April 3, 2023. The content explicitly details 'PDMR Shareholding/Share Incentive Plan' transactions, specifically reporting share purchases and matched awards for several Persons Discharging Managerial Responsibilities (PDMRs) under Article 19(1) of Regulation (EU) No. 596/2014. This type of filing, which reports insider transactions (director's dealing), corresponds directly to the 'Director's Dealing' definition. Although it is distributed via RNS, the specific content mandates the classification 'DIRS' over the general 'RNS' fallback.
2023-04-03 English
Notice of Results and Presentations
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3563 characters) released via RNS (RNS Number : 4159T) from Diaceutics PLC. The title is "Notice of Results and Presentations". It explicitly states that the company "expects to announce its audited Final Year results for the year end 31 December 2022 on 17 April 2023" and provides details for subsequent analyst and investor presentations. According to Rule 2 (The "MENU VS MEAL" Rule), a short document announcing the publication or timing of a report (like final results) is classified as a Report Publication Announcement (RPA), not the report itself (which would likely be a 10-K or IR).
2023-03-20 English
Further update regarding Silicon Valley Bank
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) on March 13, 2023. It addresses a specific, time-sensitive corporate event: the resolution of issues related to deposits held at Silicon Valley Bank (SVBUK and SVBUS) and the subsequent request to lift a temporary trading suspension on AIM. The text explicitly states it contains 'inside information for the purposes of Article 7 of Regulation (EU) 596/2014' and is disclosed under Article 17 of MAR. It is a brief update (under 5,000 characters) providing key facts and an executive comment, rather than a comprehensive report (like 10-K or IR). Since it is a regulatory announcement that doesn't fit the specific categories like DIV, DIRS, or ER, and it is clearly distributed through the official LSE news service (RNS), the most appropriate classification is the general Regulatory Filings category, RNS, as it functions as a mandatory market disclosure.
2023-03-13 English
Update regarding Silicon Valley Bank
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 7215S' and concludes with information about RNS, the news service of the London Stock Exchange. The content details an update regarding exposure to Silicon Valley Bank, the resulting liquidity impact, and the subsequent request for a temporary suspension from trading on AIM. This type of immediate, material, and non-standard corporate disclosure, especially one concerning trading suspension and regulatory compliance (mentioning MAR), is characteristic of a general regulatory announcement disseminated via the RNS system. Since it is not a full financial report (10-K, IR), a specific management discussion (MDA), or a formal proxy/dividend notice, the most appropriate classification is the general regulatory filing category.
2023-03-13 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number : 5570R' and the closing statement referencing RNS and the FCA). The content explicitly details 'PDMR Shareholding/Share Incentive Plan' transactions, specifically reporting the purchase of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and the corresponding matched share awards under an employee benefit trust/SIP scheme. This type of insider transaction reporting falls directly under the definition of Director's Dealing (DIRS) or, more broadly, a regulatory filing concerning insider transactions. Since 'DIRS' specifically covers 'Report of personal share transactions by company directors and executives (insider trades)', it is the most precise classification. Although it is an RNS filing, DIRS is more specific.
2023-03-01 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.